to treat adults with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with febrile neutropenia. The drug, also developed by Hanmi, was launched last month into a ...

Karius is proving it can add value during drug development as well ... test in determining the etiologic diagnosis of febrile neutropenia: results from a pilot study. Open Forum Infect.

Seres Therapeutics has received US Food and Drug Administration (FDA ... of antibiotic treatment and decreased incidence of febrile neutropenia for the therapy-treated subjects.

Chemotherapy-induced neutropenia is a major risk factor for infection-related morbidity and mortality and an important dose-limiting toxicity in cancer treatment. The incidence of severe ...